scholarly journals Ocular motor abnormalities in Huntington's disease

1997 ◽  
Vol 37 (24) ◽  
pp. 3639-3645 ◽  
Author(s):  
Adrian G. Lasker ◽  
David S. Zee
Neurology ◽  
1983 ◽  
Vol 33 (10) ◽  
pp. 1268-1268 ◽  
Author(s):  
R. J. Leigh ◽  
S. A. Newman ◽  
S. E. Folstein ◽  
A. G. Lasker ◽  
B. A. Jensen

2009 ◽  
Vol 24 (12) ◽  
pp. 1763-1772 ◽  
Author(s):  
Kevin M. Biglan ◽  
Christopher A. Ross ◽  
Douglas R. Langbehn ◽  
Elizabeth H. Aylward ◽  
Julie C. Stout ◽  
...  

Author(s):  
Branduff McAllister ◽  
James F. Gusella ◽  
G. Bernhard Landwehrmeyer ◽  
Jong-Min Lee ◽  
Marcy E. MacDonald ◽  
...  

Objective: To assess the prevalence, timing and functional impact of psychiatric, cognitive and motor abnormalities in Huntington's disease (HD), we analysed retrospective clinical data from individuals with manifest HD. Methods: Clinical features of HD patients were analysed for 6316 individuals in the European REGISTRY study from 161 sites across 17 countries. Data came from clinical history and the Clinical Characteristics Questionnaire that assessed eight symptoms: motor, cognitive, apathy, depression, perseverative/obsessive behavior, irritability, violent/aggressive behavior, and psychosis. Multiple logistic regression was used to analyse relationships between symptoms and functional outcomes. Results: The initial manifestation of HD is increasingly likely to be motor, and less likely to be psychiatric, as age at presentation increases. The nature of the first manifestation is not associated with pathogenic CAG repeat length. Symptom prevalence data from the patient-completed Clinical Characteristics Questionnaire correlate specifically with validated clinical measures. Using these data, we show that psychiatric and cognitive symptoms are common in HD, with earlier onsets associated with longer CAG repeats. 42.4% of HD patients reported at least one psychiatric or cognitive symptom before motor symptoms, with depression most common. Apathy and cognitive impairment tend to come later in the disease course. Each psychiatric or cognitive symptom was associated with significantly reduced total functional capacity scores. Conclusions: Psychiatric and cognitive symptoms occur before motor symptoms in many more HD patients than previously reported. They have a greater negative impact on daily life than involuntary movements and should be specifically targeted with clinical outcome measures and treatments.


2019 ◽  
Vol 29 (11) ◽  
pp. 4763-4774 ◽  
Author(s):  
Natalie E Zlebnik ◽  
Iness Gildish ◽  
Thibaut Sesia ◽  
Aurelie Fitoussi ◽  
Ellen A Cole ◽  
...  

Abstract Neuropsychiatric symptoms, such as avolition, apathy, and anhedonia, precede the onset of debilitating motor symptoms in Huntington’s disease (HD), and their development may give insight into early disease progression and treatment. However, the neuronal and circuit mechanisms of premanifest HD pathophysiology are not well-understood. Here, using a transgenic rat model expressing the full-length human mutant HD gene, we find early and profound deficits in reward motivation in the absence of gross motor abnormalities. These deficits are accompanied by significant and progressive dysfunction in corticostriatal processing and communication among brain areas critical for reward-driven behavior. Together, our results define early corticostriatal dysfunction as a possible pathogenic contributor to psychiatric disturbances and may help identify potential pharmacotherapeutic targets for the treatment of HD.


2021 ◽  
Vol 22 (11) ◽  
pp. 5911
Author(s):  
Santosh R. D’Mello

Alzheimer’s disease (AD) is a mostly sporadic brain disorder characterized by cognitive decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex whereas Huntington’s disease (HD) is a monogenic inherited disorder characterized by motor abnormalities and psychiatric disturbances resulting from selective neurodegeneration in the striatum. Although there have been numerous clinical trials for these diseases, they have been unsuccessful. Research conducted over the past three decades by a large number of laboratories has demonstrated that abnormal actions of common kinases play a key role in the pathogenesis of both AD and HD as well as several other neurodegenerative diseases. Prominent among these kinases are glycogen synthase kinase (GSK3), p38 mitogen-activated protein kinase (MAPK) and some of the cyclin-dependent kinases (CDKs). After a brief summary of the molecular and cell biology of AD and HD this review covers what is known about the role of these three groups of kinases in the brain and in the pathogenesis of the two neurodegenerative disorders. The potential of targeting GSK3, p38 MAPK and CDKS as effective therapeutics is also discussed as is a brief discussion on the utilization of recently developed drugs that simultaneously target two or all three of these groups of kinases. Multi-kinase inhibitors either by themselves or in combination with strategies currently being used such as immunotherapy or secretase inhibitors for AD and knockdown for HD could represent a more effective therapeutic approach for these fatal neurodegenerative diseases.


Sign in / Sign up

Export Citation Format

Share Document